GRI Bio, Inc. (GRI) income statement
GRINasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 6/30
$1.27−0.08 (-5.95%)
Close on Nov 18, 2026Market cap $2.78MP/E –Yield –
GRI Bio, Inc. income statement
Ratios
Latest available, balances at Jun 30, 2026
Profitability, FY
- Gross margin
- –
- Operating margin
- –
- Net margin
- –
- Return on equity, FY2025
- -238.2%
Financial strength
- Current ratio
- 10.30
- Debt to equity
- –
- Debt to assets
- –
- Cash to current liabilities
- 995.2%
Valuation
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.27
- Dividend yield
- –
See a number that looks wrong?